Association of Community Cancer Centers

Latest from Association of Community Cancer Centers


ASCO Spotlight With Randall A. Oyer, MD: Clinical Trials Must Be Accessible to Everyone

July 21, 2022

Randall A. Oyer, MD, medical director of the Ann B. Barshinger Cancer Institute, medical director of oncology, and medical director of the Cancer Risk Evaluation Program, Lancaster General Health, discusses recommendations to improve diversity in clinical trials.

Dr Randall A. Oyer: Clinical Trials Must Be Accessible to Everyone

June 01, 2022

Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent American Society of Clinical Oncology/Association of Community Cancer Centers recommendations for improving diversity in clinical trials.

City of Hope’s Alvarnas: Payers Must Recognize Cancer Care Is Different

April 17, 2022

Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.

Dr David Penberthy on ACCC Presidential Theme, Discussions for Next Year’s Meeting

March 10, 2022

David Penberthy, MD, MBA, medical director of radiation oncology at Southside Regional Medical Center, discusses his theme as president-elect of the Association of Community Cancer Centers (ACCC) and what initiatives and discussions he looks forward to addressing over the next year.

In Survivorship Care, Many Models for Communication and Value

March 03, 2022

The session opened the 48th Annual Meeting and Cancer Center Business Summit, which is the first in-person meeting in 2 years for the Association of Community Cancer Centers. The meeting is taking place March 2-4 in Washington, DC.

ACCC Presents Survey Responses on Adoption of Bispecific Antibodies

January 02, 2022

ACCC created a survey to better understand multidisciplinary cancer providers’ experiences with bispecific antibodies, with a focus on experiences with blinatumomab. Results of the survey were presented in an abstract during the 2021 American Society of Hematology Annual Meeting & Exposition.